Senti Biosciences Q1 net loss narrows on cost reduction

Senti Biosciences Holdings

14/05/2026 13:54

Overview

US biotechnology firm's Q1 revenue beat analyst expectations

Net loss narrowed yr/yr, aided by $6.9 mln gain from lease modification

Outlook

Company expects to use new financing to advance SENTI-202 clinical and manufacturing activities

Senti Bio plans to advance SENTI-202 toward pivotal trial in R/R AML following FDA feedback

Company expects operational streamlining to further reduce ongoing operating expenses

Result Drivers

COST REDUCTION - Lower research and development and general and administrative expenses, mainly from reduced external services and supplies costs

LEASE MODIFICATION GAIN - $6.9 mln gain from lease modification contributed to lower net loss

Company press release: ID:nGNX71Jv2y

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$16,000
Q1 EPS
-$0.14
Q1 Net Income
-$4.22 mln
Q1 Operating Expenses
$4.63 mln
Q1 Operating Income
-$4.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Senti Biosciences Holdings Inc is $11.50, about 1,094.2% above its May 13 closing price of $0.96

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)